CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向急性髓系白血病的协同 CAR
英文原题：Co-op CARs for targeting acute myeloid leukemia.
查看英文原题
Co-op CARs for targeting acute myeloid leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法受到抗原逃逸以及靶向肿瘤同时损伤正常组织毒性的限制。为应对这些挑战，Haubner等人开发了“IF-BETTER”策略：将具有减弱活性的CAR与协同嵌合共刺激受体结合，在保护健康祖细胞的同时增强急性髓系白血病（AML）杀伤能力，突显了利用协同CAR设计的潜力。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapies are limited by antigen escape and on-target/off-tumor toxicity. In addressing these challenges, Haubner et al. develop an "IF-BETTER" strategy. Their combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances acute myeloid leukemia (AML) killing while protecting healthy progenitors, highlighting the potential to leverage cooperative CAR designs.
论文信息
- 作者
- Kondo T、Taylor N
- 第一作者单位
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: taisuke.kondo@nih.gov.United States
- 通讯作者单位
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Université de Montpellier-IGMM, Montpellier, France. Electronic address: taylorn4@mail.nih.gov.United States
- 文献类型
- 美国 NIH 院内研究 · 评论
- 期刊
- Cancer cell2023 Nov 13
- 原文标识
- PubMed 37832553 · DOI 10.1016/j.ccell.2023.09.015